Maija Vikmane

Maija Vikmane is an Assistant Professor in the Department of Internal Diseases at the Faculty of Medicine, University of Latvia. Her academic work is deeply rooted in clinical cardiology, with a focus on arrhythmia management and therapeutic interventions.

Her research interests lie primarily in atrial fibrillation, antiarrhythmic drug efficacy, cardiac resynchronization therapy (CRT), and electrical cardioversion. She investigates the comparative effectiveness and safety profiles of drugs such as amiodarone, propafenone, and etacizine, particularly in high-risk and post-cardioversion patients. Her work contributes to optimizing clinical protocols in emergency and long-term cardiac care.

The trend in her recent publications shows a consistent focus on real-world clinical data, often comparing Latvian patient outcomes with broader European cohorts. Her studies frequently appear in the Proceedings of the Latvian Academy of Sciences, with emphasis on pharmacological interventions and device-based therapies. Topics such as sinus rhythm maintenance, recurrence risk, and heart failure management are central to her scholarly output.

Although no formal scientific awards are listed, her ongoing research activity, including conference presentations and peer-reviewed articles, reflects active scholarly engagement. She has contributed to multi-center studies and collaborative surveys, indicating integration within national and European cardiology networks.

Maija Vikmane is involved in academic and clinical mentoring through her collaborative research, though no formal advisees are listed. Her work is supported by institutional affiliations and professional recognition in clinical medicine. She is also engaged in educational activities, as evidenced by her participation in poster presentations and conference contributions.

She is part of a broader research network focused on cardiovascular diseases, collaborating with key institutions and researchers in Latvia. Her work contributes to the national fingerprint in cardiology and pharmacology, particularly in antiarrhythmic therapy and CRT implementation.